PD-L1-positive mCRPC has previously been treated with pembrolizumab and proven to exhibit anti-tumor efficacy (mCRPC). In this study, three parallel cohorts of a larger mCRPC population were used to evaluate the anti-cancer efficacy and safety of pembrolizumab monotherapy. The gene discussed is CD274; the disease is neoplasm.